Advances in artificial intelligence-driven drug development

Companies applying artificial intelligence tools in small-molecule drug discovery have recently attracted substantial financing and a multitude of large pharma partners.

Focusing on accelerated discovery, IBM Research is leveraging next-generation computing technologies—artificial intelligence, the hybrid cloud, and quantum computing—to streamline and optimize research in the healthcare and life sciences.

Scailyte’s artificial intelligence-powered platform, ScaiVision, identifies disease signatures that predict drug efficacy and describe drug mode of action to improve clinical outcomes for patients with complex diseases.

Metabolic syndrome-derived medical conditions affect billions and costs trillions. MultiOmic Health will combine artificial intelligence and wet lab experimentation with the proprietary multi-omic data it is accumulating to create new precision medicines for these conditions.

Compugen is driving the discovery and development of cancer immunotherapy drugs using its proprietary computational solutions, advanced new omics technologies and integration of computational discovery, wet-lab R&D experimentation and clinical trials.

SimBioSys is combining state-of-the-art biophysical modeling and artificial intelligence to improve precision cancer care.

Designed to reshape drug discovery and drug repositioning, systems biology company DeepLife has created a data-driven technology platform that creates digital twins of human cells, to evaluate response to new drug candidates.

Nabla Bio combines innovative artificial intelligence with proprietary wet-lab biology to design, refine and optimize next-generation therapeutic antibodies.

Sumitovant Biopharma’s DrugOME platform uses novel technologies to accelerate drug development and address unmet medical needs.

Precision medicine company Saphetor has built the world’s largest community and knowledge base for human genome variant identification, annotation, and interpretation. Through its open access platform and its clinical and application programming interface (API)-powered bespoke implementations, Saphetor helps researchers and clinicians accelerate understanding, diagnosis, and treatment of genetic conditions.

With a drug discovery platform built around patient-derived induced pluripotent stem cells and multi-omics, PurMinds NeuroPharma is de-risking the path to targeted brain therapeutics.

Vyasa has developed deep-learning artificial intelligence solutions for organizations looking to solve the complex data challenges associated with healthcare and the life sciences, from improving scientific research and accelerating drug discovery and development, to enhancing care pathways.

Exogene is using artificial intelligence to find rare, natural T cell receptors with a view to treating solid tumors and, ultimately, rejuvenating the immune system.

BIOS Health uses artificial intelligence (AI)-powered neural interfaces to understand the basis of chronic diseases and accelerate the development of treatments.

Pepticom designs ab initio novel peptide drug candidates using proprietary AI-driven biocomputational software.

Medical AI Inc.’s technology will provide fast, accurate diagnosis of cardiac problems, kidney failure, sepsis and anemia using hospital or home electrocardiogram devices.

With its unique PHARMA.AI platform, Insilico Medicine is transforming the world of drug discovery and development.

Individualized cancer therapies represent the next step for cancer immunotherapy. NEC Corporation has developed cutting-edge artificial intelligence to predict patient-specific neoantigens to turn this promise into reality and extend the approach to infectious diseases.

The biotech company’s federated platform has enabled it to accumulate some high-profile pharma and drug discovery partnerships in its five-year history.

BenchSci is on a mission to increase the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence (AI).

InterAx Biotech has developed a specialist drug discovery approach that combines artificial intelligence, integrated mathematical models and cell biology experiments to enable the early identification of safe and effective candidates.

Nucleai’s innovative biomarker platform analyzes and interprets pathology data in both research and clinical settings to enhance diagnostics and improve patient treatment outcomes.

Dompé’s Exscalate supercomputing platform is designed to accelerate drug development and is deploying an open innovation approach collaborating with top tier academic institutions, industry players and startups.

InterVenn is pioneering artificial intelligence-driven glycoproteomic analysis for novel biomarker identification to generate highly accurate diagnostics to guide targeted therapies and to fuel drug discovery and development.